Effect of Serelaxin Versus Standard of Care in Acute Heart Failure (AHF) Patients
Status:
Terminated
Trial end date:
2017-04-25
Target enrollment:
Participant gender:
Summary
This was a multinational, multicenter, randomized, open-label study to confirm and expand the
efficacy, safety and tolerability evidence of 48 hours intravenous infusion of serelaxin (30
micrograms/kg/day) when added to Standard of Care (SoC) in patients admitted to hospital for
Acute Heart Failure (AHF).